Biotechnology

Armata Pharmaceuticals posts a staggering $174M annual loss, triggering a 'going concern' alert, yet its promising phage therapy pipeline advances.

Weave Bio forms a star-studded advisory board with leaders from Gilead and Takeda to navigate the high-stakes world of AI in drug development.

Growth equity firm SEMCAP launches a new fund with Unilever Prestige visionary Vasiliki Petrou, targeting the booming wellness and longevity market.

Early data for VG801 shows vision improvement in Stargardt disease patients, leveraging novel tech and fast-track FDA support to tackle a leading cause of blindness.

A potential first-ever treatment for a severe rare skin disease gets a major boost from the FDA, accelerating its path to patients and exciting investors.

Enlivex reported a staggering $1.23 billion profit, not from its labs, but from a risky treasury of crypto assets. Is this genius or a gamble?

Riding high on record 2025 results and a new FDA approval, LivaNova faces intense scrutiny ahead of its May 6 earnings call. Can it sustain the momentum?

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.

New data reveals Otsuka's VOYXACT clears key markers of kidney damage in IgA nephropathy, offering new hope beyond symptom management for patients.

With CE Mark approval, Countable Labs brings single-molecule counting PCR to Europe, promising unprecedented precision for gene therapy and diagnostics.

Following a 40-year career shaping biotech finance, Jessica Chutter's move to PTC's board signals major strategic ambitions for the rare disease firm.

Biolojic Design's adaptive AI drug for asthma and eczema hits a key milestone with Teva, heralding a new era for personalized autoimmune treatment.

Swedish biotech VERIGRAFT begins a pivotal trial for a personalized, lab-grown vein, offering hope for a true cure for millions with chronic venous insufficiency.

As funding expires for Wayne State's 35-year heart experiments on dogs, advocates and lawmakers urge the NIH to end a legacy of waste and suffering.

Venture capital leaders and national security experts caution that drug pricing controls and regulatory hurdles could cede America's biomedical edge to rivals.

A breakthrough in mycelium-based infection detection has prompted Mushrooms Inc. to halt a merger, betting its future on its own innovative biotech platform.

A new strategic partnership between Perceptive eClinical and Kayentis promises to ease clinical trial complexity by integrating key technology platforms.

Apimeds Pharmaceuticals accuses its Korean partner of an illegal board seizure, sparking a high-stakes legal fight in Delaware and Seoul over a broken merger.

Experic and Flurry Powders form a strategic alliance to accelerate complex therapies by combining advanced particle engineering with GMP manufacturing.

Xtressé's Xvie, an injectable therapy using extracellular vesicles, has been cleared for human trials, offering new hope for androgenetic alopecia.